Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622 is registered in ClinicalTrials.gov with AriBio Co., Ltd. as lead sponsor.

NCT NCT03625622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03625622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Lead sponsor
AriBio Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
April 1, 2019
Completion date
June 28, 2021
Enrollment
210 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate alzheimer's disease